drugset

drugset / Trial / NCT00189579

Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer

NCT00189579 ↗

Phase 2 Terminated 45 enrolled ARCAGY/ GINECO GROUP Hoffmann-La Roche · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.

Timeline

Start: —
Primary completion: —
Completion: 2007-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trastuzumab	Monoclonal antibody	—	—

Indications